Myelodysplastic Syndromes

>

Latest News

Characteristics including Ogata score and phenotypic aberrancies may correlate with mutational patterns that are predictive of treatment response in patients with myelodysplastic syndrome.
Flow Cytometry/Cytomorphological Features Correlate with MDS Prognosis

September 11th 2023

Characteristics including Ogata score and phenotypic aberrancies may correlate with mutational patterns that are predictive of treatment response in patients with myelodysplastic syndrome.

Luspatercept may provide clinical benefit regardless of subgroup and baseline mutation burden in transfusion dependent patients with myelodysplastic syndrome with anemia, according to Guillermo Garcia-Manero, MD.
Luspatercept Controls Anemia in Transfusion Dependent MDS Population

September 8th 2023

Patients with dyserythropoiesis appear to have higher PD-L1 expression than those without in a study population of those with myelodysplastic syndromes.
PD-L1 Expression Confers Worse Myelodysplastic Syndrome

September 6th 2023

Luspatercept, which is supported by results from the phase 3 COMMANDS trial presented at 2023 ASCO, is now available for patients with low-risk myelodysplastic syndrome.
FDA Approves Frontline Luspatercept for Anemia Related to Low-Risk MDS

August 29th 2023

Findings from the phase 2/3 IMerge trial support the new drug application for imetelstat in the treatment of patients with transfusion-dependent anemia in lower-risk myelodysplastic syndrome.
FDA Accepts New Drug Application for Imetelstat in Lower-Risk MDS

August 22nd 2023

Video Interviews

More News